Effect of Antacids on the Pharmacokinetics of Raltegravir

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00944307
Recruitment Status : Completed
First Posted : July 23, 2009
Last Update Posted : June 28, 2017
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The purpose of this study is to test whether there is a drug interaction between raltegravir (a medicine used to treat the human immunodeficiency virus or HIV) and antacids.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: raltegravir Drug: antacid Phase 1

Detailed Description:
This study will determine if an interaction occurs between the HIV medicine raltegravir and an antacid. A prior study found an interaction with another medicine like raltegravir called elvitegravir and an antacid. The elvitegravir levels were reduced by half. The same interaction may occur with raltegravir and an antacid based on the structure of this medicine and how it works. When the levels of HIV medications are reduced, people with HIV can "fail" their treatment. The virus can multiply when the drug levels are too low and the medications can stop working. We need to be sure that antacids will not cause this problem with raltegravir.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers
Study Start Date : July 2009
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Active Comparator: raltegravir alone
Subjects will receive a single dose of 400 mg raltegravir orally
Drug: raltegravir
raltegravir 400mg orally once
Other Name: Isentress

Experimental: raltegravir plus antacid
Subjects will receive a single dose of 400mg raltegravir orally simultaneously with an antacid
Drug: raltegravir
raltegravir 400mg orally once
Other Name: Isentress

Drug: antacid
aluminum, magnesium, simethicone-containing antacid 30mL orally once
Other Name: Isentress, Maalox Plus Extra Strength

Primary Outcome Measures :
  1. Raltegravir AUC with and without an antacid [ Time Frame: 0-48 hours ]

Secondary Outcome Measures :
  1. Raltegravir Cmax with and without an antacid [ Time Frame: 0-48 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Absence of HIV-1 infection as documented by any licensed ELISA test kit within 21 days prior to study entry.
  • Age greater than or equal to 18 but less than or equal to 60 years.
  • Ability and willingness to give written informed consent.
  • Within 30% (+/-) of ideal body weight and total body weight of ≥ 50 kg.
  • Hematology, Metabolic Profile, Renal, and Hepatic Function tests all within normal limits.
  • Creatine kinase (CK) less than 3 times the upper limit of normal

Exclusion Criteria:

  • Pregnancy or breast-feeding.
  • Women and men of reproductive potential who are actively engaging in sexual activity or assisted reproductive technology with the intent of pregnancy.
  • Allergy/sensitivity to raltegravir.
  • Allergy/sensitivity to antacids.
  • Active drug or alcohol abuse or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. While on study, subjects will be instructed not to consume alcohol for 48 hours prior the screening visit, and for the 24 hours preceding the intensive pharmacokinetic (PK) study visits and for 24 hours following the completion of the study visits.
  • Any medical condition that, in the opinion of the investigator, would interfere with the subject's ability to participate in this protocol.
  • Participation in any investigational drug studies within 30 days prior to study entry.
  • History of or active cardiovascular, renal, hematologic, hepatic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease(s). This is inclusive of chronic illnesses such as hypertension, coronary artery disease, arthritis, diabetes, any chronic gastrointestinal conditions that might interfere with drug absorption.
  • Use of investigational, prescription, and over-the-counter medications within 14 days of study entry with the following exceptions: aspirin, acetaminophen, ibuprofen, and oral contraceptives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00944307

United States, Colorado
University of Colorado Denver
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Principal Investigator: Jennifer J Kiser, PharmD University of Colorado, Denver

Responsible Party: University of Colorado, Denver Identifier: NCT00944307     History of Changes
Other Study ID Numbers: 09-0475
First Posted: July 23, 2009    Key Record Dates
Last Update Posted: June 28, 2017
Last Verified: June 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Colorado, Denver:
drug interaction
human immunodeficiency virus

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Raltegravir Potassium
Aluminum hydroxide, magnesium hydroxide, simethicone drug combination
Anti-Ulcer Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents
Protective Agents
Physiological Effects of Drugs